Karim Kasmi
Company: Boehringer Ingelheim
Job title: Senior Principal Scientist
Seminars:
Closing Panel: The Future of Innate Immune Checkpoints & Activation 2:30 pm
Delving into the horizons of homing of innate cells and reprograming of the tumor microenvironment Discussing novel checkpoint inhibitors Analysing the various immunotherapy approaches discussed & beyond Updates on clinical trials for immunotherapies In vitro models and discovery technologies for innate cell-based therapies New methodologies of analyzing innate immune cells in the tumor microenvironment (scRNAseq,…Read more
day: Innate Immune Checkpoints & Activation Pre-Focus Day
The Anti-Fibrotic Drug Nintedanib Promotes Resolution Phenotype Macrophages 1:30 pm
day: Innate Immune Checkpoints & Activation Pre-Focus Day